Bladder Cancer Clinical Trial
Official title:
A Multicentre Phase II Trial to Determine the Efficacy of the Anti-Tyrosine Kinase Sunitinib (Sutent®) as Second Line Therapy in Patients With Transitional Cell Carcinoma (TCC) of the Urothelium Which Failed or Progressed After First Line Chemotherapy for Advanced or Metastatic Disease
Verified date | July 2009 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying sunitinib to see how well it works as second-line
therapy in treating patients with locally advanced or metastatic transitional cell cancer.
Status | Completed |
Enrollment | 80 |
Est. completion date | |
Est. primary completion date | May 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed transitional cell cancer of the urothelium - Advanced or metastatic disease - Disease failed or progressed after first-line chemotherapy - At least 1 non-irradiated measurable lesion assessed by CT scan or MRI according to RECIST - No progressive brain metastases PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - ANC = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Hemoglobin = 8g/dL - Total bilirubin = 1.5 times upper limit of normal (ULN) - AST and ALT = 2.5 times ULN (= 5 times ULN in presence of liver metastases) - Creatinine clearance = 40 mL/min - PTT and INR = 1.5 times ULN - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during study treatment - No uncontrolled high BP, defined as > 150/100 mm Hg despite treatment - No diagnosis of a second malignancy within the past 5 years, except for basal cell or squamous cell carcinoma of the skin, incidental PT2 prostate cancer found on radical cystoprostatectomy material, or carcinoma in situ of the cervix, that has been adequately treated with no evidence of recurrence in the past 12 months - None of the following within the past 12 months: - Myocardial infarction - Severe/unstable angina pectoris - Coronary artery bypass graft - Symptomatic congestive heart failure - Cerebrovascular accident - Transient ischemic attack - Pulmonary embolism - At least 6 months since deep vein thrombosis - No NCI CTCAE grade 3 hemorrhage within the past 4 weeks - No pre-existing neuropathy = NCI CTCAE grade 2 - No history of interstitial pneumonitis or pulmonary fibrosis - No ongoing cardiac arrhythmias = NCI CTCAE grade 2, atrial fibrillation of any grade, or prolongation of the QTc interval (> 450 msec for males or > 470 msec for females) - No ongoing active infection - No patients deprived of liberty or who are under supervision (including a trusteeship) - No psychological, familial, sociological, or geographic condition potentially hampering compliance with study treatment and follow-up - Patients must be affiliated to a social security system PRIOR CONCURRENT THERAPY: - Prior platinum-based therapy allowed - No prior sunitinib malate - No prior radiotherapy to = 25% of marrow producing area - Prior neoadjuvant or adjuvant chemotherapy allowed - More than 2 weeks since prior and no concurrent oral anticoagulant agents at therapeutic doses - Low molecular weight heparin allowed - At least 30 days since prior chemotherapy or radiotherapy and recovered - No other concurrent anticancer treatment, including experimental agents, or participation in another investigational trial |
Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Centre Rene Huguenin | Saint Cloud | |
France | Hopital Foch | Suresnes |
Lead Sponsor | Collaborator |
---|---|
Centre Rene Huguenin |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response as assessed by RECIST criteria | No | ||
Secondary | Progression-free survival | No | ||
Secondary | Overall survival | No | ||
Secondary | Time to response and duration of response | No | ||
Secondary | Safety | Yes | ||
Secondary | Quality of life | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |